Search | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Interviews with the Experts: Hemolysis in PNH and Beyond

    What is hemolysis and what its relationship to PNH? Hemolysis is a term we use to describe destruction and/or rupture of red blood ...

    Interview last updated 08/31/2016 - 8:40am.

  2. Toward complement inhibition 2.0: Next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria

    ... efficacy in prevention of C3-mediated extravascular hemolysis , in addition to inhibition of intravascular hemolysis, eventually leading to improved hematological responses. The ...

    Research Article last updated 04/11/2018 - 10:54am.

  3. Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment

    ... characterized by complement-mediated intravascular hemolysis that is effectively treated with eculizumab . However, ... heterogeneous with some patients presenting residual hemolysis and requiring RBC transfusions. Recent reports have shown that both ...

    Research Article last updated 10/06/2016 - 8:50am.

  4. A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms

    ... of normal unless attributable to underlying disease, hemolysis or documented Gilbert’s syndrome. AST (SGOT)/ALT (SGPT) < ...

    Clinical Trial last updated 05/14/2018 - 2:02pm.

  5. T Cell Transcriptomes from Paroxysmal Nocturnal Hemoglobinuria Patients Reveal Novel Signaling Pathways

    ... a life-threating disease characterized by intravascular hemolysis , bone marrow (BM) failure, and venous thrombosis . ...

    Research Article last updated 07/27/2017 - 2:06pm.

  6. T Cell Transcriptomes from Paroxysmal Nocturnal Hemoglobinuria Patients Reveal Novel Signaling Pathways

    ... a life-threating disease characterized by intravascular hemolysis , bone marrow (BM) failure, and venous thrombosis . ...

    Research Article last updated 07/11/2017 - 10:43am.

  7. A Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

    ... Total bilirubin ≥ 1.5 mg/dL not related to hemolysis or Gilbert’s disease i.          Alanine ...

    Clinical Trial last updated 05/04/2018 - 3:53pm.

  8. Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria

    ... is characterized by complement-mediated intravascular hemolysis due to the lack of CD55 and CD59 on affected erythrocytes. The ... possibly leading to clinically meaningful extravascular hemolysis. We investigated the effect of the peptidic C3 inhibitor compstatin ...

    Research Article last updated 03/06/2014 - 11:17am.

  9. Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry.

    ... (PNH) is characterized by chronic, complement-mediated hemolysis , frequently leading to debilitating clinical symptoms and ... multivariate analysis showed that PNH patients with elevated hemolysis [ lactate dehydrogenase (LDH) levels ≥1.5 times the upper ...

    Research Article last updated 06/20/2013 - 11:07am.

  10. Improving cytopenia with splenic artery embolization in a patient with paroxysmal nocturnal hemoglobinuria on eculizumab

    ... stem cell disorder characterized by intravascular hemolysis , aplasia and an increased risk of thrombosis . We describe ...

    Research Article last updated 01/08/2014 - 9:53am.